ALN-PCSSC

DRUG3 trials

Sponsors

Alnylam Pharmaceuticals, The Medicines Company

Conditions

Atherosclerotic Cardiovascular DiseaseDiabetesFamilial HypercholesterolemiaHomozygous Familial HypercholesterolemiaHypercholesterolemia

Phase 1

A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

CompletedNCT02314442

Alnylam PharmaceuticalsHypercholesterolemia

Start: 2014-12-31End: 2015-11-30Updated: 2015-12-17

Phase 2

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

CompletedNCT02597127

The Medicines CompanyAtherosclerotic Cardiovascular Disease, Diabetes, Familial Hypercholesterolemia

Start: 2016-01-31End: 2017-06-07Updated: 2019-05-17

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

CompletedNCT02963311

The Medicines CompanyHomozygous Familial Hypercholesterolemia

Start: 2016-12-13End: 2018-10-08Updated: 2020-05-18

Related Papers

Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial

Circulation2025-05-207 citations

A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.

2023-12-194 citations

Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

Circulation2023-10-1869 citations

Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease.

2020-02-27162 citations

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies.

2019-10-1799 citations

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels

JAMA Cardiology2019-09-25159 citations

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Diabetes Care2018-11-28109 citations

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins

Circulation2018-05-07152 citations

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

New England Journal of Medicine2017-03-17950 citations

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

New England Journal of Medicine2016-11-13738 citations